The relationship between the adipocyte-derived hormone leptin, insulin resistance, and fat redistribution in patients with human immunodeficiency virus (HIV) infection has not been established. We classified a cohort of HIV type 1 (HIV- ). Mean leptin levels P ! .001 ‫ע(‬ standard deviation) were lowest in patients with lipoatrophy ( ng/mL), highest in patients with 1.76 ‫ע‬ 1.20 lipohypertrophy ( ng/mL), and significantly different from those in patients without lipodystrophy 9.10 ‫ע‬ 6.86 ( ng/mL; both ). In this cohort of antiretroviral-experienced HIV-infected patients, a low 3.14 ‫ע‬ 2.30 P ! .01 serum level of leptin was independently associated with insulin resistance in patients with lipoatrophy, after controlling for total and regional body fat.
leptin correlate positively with total and central fat accumulation and are associated with insulin resistance [6] [7] [8] . Leptin deficiency or leptin resistance due to mutations of the leptin receptor in rodents can lead to hyperinsulinemia and the development and persistence of obesity and insulin resistance. In addition, exogenous leptin administration can restore insulin sensitivity in leptin-deficient lipoatrophic mice, independently and before the occurrence of any changes in the body weight of such mice [9, 10] . In humans, both congenital lipoatrophy and acquired lipoatrophy are characterized by a generalized loss of subcutaneous and visceral fat, insulin resistance, and hyperlipidemia [11] [12] [13] . Recently, it was demonstrated that leptin replacement in adults with acquired and congenital lipodystrophy syndromes resulted in improved glycemic control and decreased triglyceride levels, allowing for the decrease or discontinuation of antidiabetic therapy [14] .
The use of HAART for HIV infection has resulted in remarkable decreases in morbidity and mortality in this patient population as a result of the suppression of viral replication. Because patients with HIV infection are living longer, however, body fat distribution abnormalities and metabolic derangements are becoming increasingly apparent. Estimates of the prevalence of lipodystrophy syndrome are as high as 84% for patients taking protease inhibitors (PIs) and 41% for PInaive patients [15] [16] [17] [18] . As with patients with congenital lipodystrophy syndromes, patients with HIV lipodystrophy also manifest various metabolic abnormalities. Lipid abnormalities (elevated total cholesterol, triglyceride, and low-density lipoprotein [LDL] cholesterol levels and a decreased high-density lipoprotein [HDL] cholesterol level) are seen in up to 60% of patients treated with PIs [19, 20] , whereas impaired glucose tolerance occurs in up to 47% of such patients [21, 22] . Given the similarities between the metabolic complications observed in patients with HIV-related lipodystrophy and those seen in patients with other lipodystrophy syndromes, we sought to investigate further the relationship between leptin and the HIV-related fat redistribution syndrome. To date, there have been a small number of studies reporting leptin levels in HIVinfected patients with lipodystrophy. These studies provided conflicting findings regarding the relationship between leptin and fat redistribution, but they did not evaluate subjects with different patterns of fat redistribution separately [1, [23] [24] [25] [26] [27] [28] . We evaluated the association between leptin, the various phenotypic manifestations of lipodystrophy, and the metabolic profiles while controlling for several potential confounders, including regional and total body fat, exercise, the CD4 ϩ T cell count at baseline, and the use of HAART.
PATIENTS AND METHODS
Study population. Patients were recruited from 2 ambulatory care HIV clinics at an urban academic medical center and were eligible for inclusion if, at the time of the study, they were infected with HIV, were 116 years of age, and had received у6 months of cumulative exposure to any antiretroviral regimen (PI-experienced and PI-naive patients were included). The study was approved by the Committee on Clinical Investigation (CCI) of the Beth Israel Deaconess Medical Center (Boston, MA) and was conducted with the written consent of each participant. Guidelines for human experimentation from the US Department of Health and Human Services (Washington, DC) and the CCI of Beth Israel Deaconess Medical Center were followed in the conduct of this research project. Study visit. One hundred twenty-six patients were interviewed using a detailed questionnaire administered by one of the study investigators, and medical records were reviewed to confirm the information reported by the patients. Patients were examined, and anthropometric measurements (of skin folds, the waist-to-hip ratio, body mass index (BMI), and the widest diameter of the "buffalo hump," when present) were made in a standardized fashion. Digital photographs of predetermined views (i.e., the face, gluteus region, legs, arms, and chest, as well as a full side view) were taken for documentation of body fat distribution. A fat redistribution adjudication committee that consisted of investigators not involved in the patient interviews, data collection, or data analysis reviewed the standard photographs of each patient, together with the anthropometric measurements, and they then classified the patients as belonging to 1 of 4 subgroups: the no lipodystrophy group (i.e., the No LD group), the lipoatrophy group (i.e., the LA group; patients had subcutaneous fat loss involving the face, gluteus region, and extremities), the lipohypertrophy group (i.e., the LH group; patients had fat accumulation consisting of a buffalo hump, central adiposity, or multiple lipomas), or the mixed lipodystrophy group (i.e., the MLD group; patients had features of both lipoatrophy and lipohypertrophy) [29] . Adjudication was conducted by following strict criteria outlined within the study protocol.
Laboratory analysis. On the day of the study visit, fasting blood samples were obtained to measure leptin, insulin, glucose, and lipid levels. Leptin and insulin levels were assayed by commercially available radioimmunoassay (RIA) kits (manufactured by Linco Research [for assessment of leptin levels] and DSL [for assessment of insulin levels]). The lower limits of detection of the assays were 0.5 ng/mL for leptin and 1.3 mIU/ mL for insulin. The intra-assay coefficients of variation were 5%-8% for leptin and 4.5%-8.3% for insulin. Current data on the CD4 ϩ T cell count and the HIV load were extracted from the medical record by use of values obtained within 4 weeks of the study visit. The CD4 ϩ T cell count at the time of diagnosis of HIV infection was obtained from the patients' electronic medical records. Insulin resistance was determined using the homeostasis model assessment index (HOMA-IR) with the following formula: (fasting insulin level in microunits per milliliter ϫ glucose level in millimoles per liter)/22.5. Fasting lipoprotein fractions were measured as described elsewhere [30, 31] . Plasma and lipoprotein fractions were assayed for total cholesterol and triglyceride by use of an Abbott Spectrum analyzer with the use of enzymatic reagents [32] . HDL cholesterol was measured as described elsewhere [30] . For analysis of categorical variables (demographic characteristics and antiretroviral drug use), the x 2 test was used, and, for post hoc subgroup analysis, Fisher's exact test was used, with adjustment of P values as described above. Spearman correlation coefficients were derived for each lipodystrophy subgroup to evaluate the relationship between leptin levels and the other metabolic laboratory values measured (i.e., total cholesterol, HDL cholesterol, LDL cholesterol, triglyceride, glucose, and insulin levels and HOMA-IR). Multiple linear regression analysis was performed to evaluate leptin as a predictor of lipid, glucose, and insulin levels and HOMA-IR, after adjustment for age, sex, exercise, total nucleoside reverse-transcriptase inhibitor (NRTI) use (i.e., the cumulative duration of use of all NRTIs, in months), and CD4 ϩ T cell count at diagnosis of HIV infection. Logistic regression analysis was performed, with adjustment for the same independent variables, to assess whether leptin was an independent predictor of patients belonging to one of the lipodystrophy subgroups versus the No LD group. For linear and logistic regression analysis, variables were included if they were found to be statistically significant in univariate analysis and if they were thought to be associated with lipodystrophy. For all analyses, P !.05 was considered to be statistically significant.
RESULTS
Baseline demographic and anthropometric characteristics of study subjects. One hundred twenty-six patients with HIV infection were enrolled in the study; 120 of the 126 patients were adjudicated into 1 of 4 body fat redistribution categories: 51 (43%) were in the No LD group, 23 (19%) were in the LA group, 29 (24%) were in the MLD group, and 17 (14%) were in the LH group (table 1) . Six patients who could not be adjudicated because of a lack of consensus within the adjudication committee were not included in the analyses. When analyses of the baseline variables according to lipodystrophy subgroup were performed, there were a number of significant differences. There were differences in sex distribution between the 4 groups ( ), with there being a higher P ! .05 percentage of men in the LA group (22 patients [96%] ; data not shown). However, P p .04 analysis of subgroups according to lipodystrophy category did not reveal any significant differences in race/ethnicity. There was a statistically significant difference in the mean age of the patients (
) and in the amount of exercise between groups P ! .05 ( ). In the overall analysis, there was no difference with P ! .01 regard to current or past smoking status (yes/no), total tobacco use (i.e., the number of packs of cigarettes smoked per week multiplied by number of years that the subjects smoked), extent of current alcohol use (i.e., number of drinks per week), coinfection with hepatitis B or C (defined as a positive result of a hepatitis B surface antigen test or hepatitis C antibody test), or duration since diagnosis of HIV infection (number of months) (data not shown).
With regard to virologic and immunologic characteristics, there was a statistically significant difference between subgroups regarding the CD4 ϩ T cell count at diagnosis of HIV infection, such that patients in the LH and MLD groups had lower CD4 ). P p .02 There were statistically significant differences between the 4 lipodystrophy groups with regard to anthropometric and physical (body fat distribution) characteristics, findings that would be expected (given our subclassification of patients), and findings that affirmed the adjudication of subjects appropriately into each of the 4 subgroups (table 1) . Specifically, there were differences between the groups with regard to BMI; the percentage of total body fat; abdominal fat and lower limb fat (as determined by DEXA); the ratio of abdominal fat to lower limb fat (as determined by DEXA); total, abdominal subcutaneous, and abdominal visceral fat (as determined by CT); and the waist-to-hip ratio ( for all of these measures); there P ! .0001 were also differences regarding the percentage of visceral fat (as determined by CT) ( ) and weight ( Metabolic and hormonal measurements. There were statistically significant differences between the 4 subgroups regarding the levels of HDL cholesterol, triglycerides, and insulin, and, also, HOMA-IR ( Spearman correlation analysis for the entire cohort of patients revealed a significant correlation between leptin and total cholesterol, HDL cholesterol, and insulin levels, and HOMA-IR ( ; data not shown). Subgroup analysis for the No LD P ! .05 group revealed correlations between leptin and both the insulin level and HOMA-IR ( for each analysis). There were no P ! .05 significant bivariate correlations for subjects in the LA, LD, or MLD groups.
Multiple linear regression analysis evaluating the relationship between leptin and the measured metabolic variables, with controlling for age, sex, total exercise, total NRTI use, and the CD4 ϩ T cell count at diagnosis of HIV infection, revealed independent associations of leptin with the insulin level and HOMA-IR for subjects in the LA group ( ), and with P ! .01 total cholesterol and triglyceride levels for subjects in the LH group (  ; table 2 ). Total exercise performed by the study P ! .05 participants was evaluated using 3 multiple-choice questions, with the type of exercise coded as 1 (walking on level ground and/or swimming), 2 (running, participation in aerobic classes, and/or use of cardiovascular conditioning machine, such as a treadmill or stationary bike), or 3 (weight training), and with intensity coded as 1 (slight exercise), 2 (moderate exercise), or 3 (heavy exercise). Exercise frequency ranged from 0-7 or more sessions per week, and the duration of exercise was classified as either !15 min, 15-29 min, 30-59 min, 60-89 min, or 190 min per session. Cumulative indexes for either aerobic or total (i.e., aerobic and/or resistance) exercise were calculated using the following formula: intensity scale ϫ duration in minutes ϫ number of sessions per week.
A similar multiple linear regression model was constructed, with adjustment for all of the aforementioned variables as well as for total PI use, lower limb fat (as determined by DEXA), and visceral fat (as determined by CT)-3 additional variables that were added because of their potential relationship to insulin resistance. Addition of these variables to the model did not change the results for the LA group; leptin remained associated with both insulin ( , ; b effect ‫ע‬ SE 35.981 ‫ע‬ 5.679 ) and HOMA-IR ( , ; P ! .001 b effect ‫ע‬ SE 6.596 ‫ע‬ 1.404 P p ) in the LA group (data not shown). In the LH group, .001 leptin did not remain associated with total cholesterol or triglycerides, and, in the No LD group, there was a new association between leptin and insulin that was not seen in the original model ( , ; ). b effect ‫ע‬ SE 1.159 ‫ע‬ 0.562 P ! .05 Logistic regression analysis is shown in table 3. After controlling for age, sex, total exercise, total NRTI use, and CD4 ϩ T cell count at diagnosis of HIV infection was done, leptin was independently associated with lipoatrophy (adjusted OR, 0.445; 
DISCUSSION
The HIV-related lipodystrophy syndrome is increasingly recognized. However, there are many questions that remain unanswered with regard to the syndrome itself and the metabolic abnormalities with which it is associated, specifically the relationship between leptin, insulin resistance, and fat redistribution.
In the present observational study, we demonstrated that there are significant associations between leptin levels and insulin resistance in patients with distinct HIV lipodystrophy phenotypes. We carefully classified patients with regard to the presence of lipoatrophy, lipohypertrophy, or both, and we then evaluated the relationship between leptin and metabolic abnormalities seen in association with the HIV-1 lipodystrophy syndrome. Patients with lipoatrophy have the lowest leptin levels, patients with lipohypertrophy have the highest levels, and patients with either mixed lipodystrophy or no lipodystrophy have intermediate levels. Previous studies evaluating leptin levels in patients with HIV-related lipodystrophy have reported conflicting results, with some studies suggesting a relationship between leptin and lipodystrophy, and with other studies demonstrating no relationship [1, [25] [26] [27] . Our results are in agreement with those of Estrada et al. [33] , who recently demonstrated that fat loss in the extremities of HIV-1-infected men was associated with low levels of leptin, increased visceral fat, and metabolic abnormalities. Vigouroux et al. [24] found that HIV-related lipodystrophy was associated with insulin resis-tance, overt diabetes mellitus, and an elevated triglyceride level, but this group found no difference in leptin levels between patients with or without HIV-related lipodystrophy. Christeff et al. [34] did not find a correlation between leptin and lipodystrophy, but they found elevated levels of leptin overall. It is possible that the conflicting results of these studies are the result of the inclusion of all patients with lipodystrophy, without further stratification by pattern of lipodystrophy. If patients with both lipoatrophy and lipohypertrophy had been analyzed together in one group, the relationships between leptin, lipoatrophy, lipohypertrophy, and insulin resistance that we demonstrated in this study might not have been apparent.
Leptin is produced by adipocytes, and low levels are a consequence of low fat stores in a patient. Thus, the leptin deficiency that we report in patients with HIV-related lipoatrophy in the present study may be a result of fat loss, with decreased synthesis and release of leptin from adipocytes. In contrast, the elevated leptin levels seen in patients with HIV-related lipohypertrophy may signify a state of leptin resistance or overproduction by increased adipose tissue mass. The insulin resistance seen in patients with the lipohypertrophy and mixed lipodystrophy phenotypes in our study was not independently associated with leptin levels, but the relationship between leptin-binding protein or free leptin and insulin resistance in individuals with HIV-related lipohypertrophy is unclear and needs to be studied further.
We have demonstrated that there is a relationship between leptin levels and insulin resistance in individuals with HIVrelated lipoatrophy, independent of either central or peripheral fat mass. It is possible that abnormal leptin levels may develop as a consequence of fat wasting in this subgroup of patients, and that hypoleptinemia may subsequently contribute to the metabolic abnormalities seen in association with HIV-related lipoatrophy. Ongoing interventional studies that involve administration of leptin to leptin-deficient subjects with HIVrelated lipoatrophy are expected to prove whether the leptin deficiency is causally related to the metabolic abnormalities associated with lipoatrophy. The beneficial effect of leptin replacement on the metabolic parameters in adult women with congenital and acquired lipodystrophy and hypoleptinemia has recently been demonstrated in a small study [14] , and it is reasonable to consider, given the many similarities between the syndromes, that leptin replacement may also prove to be of benefit in hypoleptinemic patients with HIV-related lipoatrophy and insulin resistance. Additional prospective studies that involve larger groups of patients who manifest the different lipodystrophy phenotypes must be done to confirm our findings and to further elucidate the complex relationship between leptin and the HIV-associated lipodystrophy syndrome.
